CHMA: Chiasma, Inc. - Summary | Jitta

Chiasma, Inc.

NASDAQ:CHMA

Notice
Stock data is unavailable or the company’s delisted.
Price
$3.76
Loss Chance
58.4%
0.44JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (9)
Recent Business Performance (39)
Financial Strength (41)
Return to Shareholders (0)
Competitive Advantage (10)
Jitta Signs
Recent Business PerformanceEarning decline 107.88% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.44
100.00%
3.03
208.71%
3.05
163.37%
Pharmaceuticals
5.41
68.59%
5.05
81.20%
2.69
94.10%
COMPANY DESCRIPTION
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.